Novartis

While not offering any specifics, investors seemed comfortable enough with Dennis Lockhart's comments to end the week on a positive note. While speaking to CNBC the Atlanta Fed chief commented that tapering will begin “when the economy is ready and when the market is ready.” Lockhart also noted...

Among leading biotech and emerging pharmaceutical companies, short sellers moved on BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Regeneron Pharmaceuticals (NASDAQ: REGN) the most between the August 30 and September 13 settlement dates. The number of shares sold short in...

This weekend in Barron's online: managing health care expenses for the long term, as well as the prospects for GE, Nexstar Broadcasting, United Rentals, Approach Resources and more. Cover Story "How to Protect Your Health and Wealth" by Beverly Goodman. In this week's cover story in Barron's,...

Among leading biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw significant percentage declines in short interest between the July 31 and August 15 settlement dates. Short sellers also shied away...

On Sunday, after months of trying to work out a deal, Amgen (NASDAQ: AMGN) and Onyx (NASDAQ: ONXX) announced that Amgen will acquire Onyx for $125 per share valuing the deal as $10.4 billion. The announcement is about as much of a surprise as those two flirtatious coworkers that later told...

Apple (NASDAQ: AAPL), CBS (NYSE: CBS), Merck (NYSE: MRK) and Wal-Mart (NYSE: WMT) all have or are expected to have monster stock repurchase plans of more than $5 billion. Below, we take a quick look at how these stocks have fared and what analysts expect from them. When it comes to returning...

Among biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Onyx Pharmaceuticals (NASDAQ: ONXX) and Pharmacyclics (NASDAQ: PCYC) saw the most significant percentage declines in short interest between the June 28 and July 15 settlement dates. Short sellers also shied away from...

Among biotech and emerging pharmaceutical companies, Gilead Sciences (NASDAQ: GILD) and Onyx Pharmaceuticals (NASDAQ: ONXX) saw the most significant rises in short interest between the June 14 and June 28 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena...

Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new team includes recommendations to buy shares of Antares Pharma (NASDAQ: ATRS), Intercept Pharmaceuticals (NASDAQ: ICPT), Questcor Pharmaceuticals (NASDAQ: QCOR) and ViroPharma...

Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest between the May 15 and May 31 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Dendreon (NASDAQ: DNDN), Onyx Pharmaceuticals (NASDAQ: ONXX)...